CRISPR Therapeutics AG (CRSP) Current Leases (2019 - 2026)

CRISPR Therapeutics AG has disclosed Current Leases across 8 years of filings, most recently posting $18.6 million for Q1 2026.

• Current Leases for Q1 2026 came in at $18.6 million, up 6.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.6 million (up 6.32% YoY), and the FY2025 annual result was $18.6 million, up 7.46% from the prior year.
• Current Leases came in at $18.6 million for Q1 2026 at CRISPR Therapeutics AG, roughly flat from $18.6 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $18.6 million in Q1 2026 to a low of $8.3 million in Q2 2022.
• The 5-year median for Current Leases is $16.0 million (2024), against an average of $15.6 million.
• Across the five-year window, Current Leases sank 47.92% in 2022 and soared 79.42% in 2023, its largest moves.
• CRISPR Therapeutics AG's Current Leases stood at $15.8 million in 2022, then decreased by 1.37% to $15.6 million in 2023, then rose by 10.64% to $17.3 million in 2024, then grew by 7.46% to $18.6 million in 2025, then climbed by 0.18% to $18.6 million in 2026.
• The last three Current Leases figures came in at $18.6 million (Q1 2026), $18.6 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.